Idarucizumab (Praxbind(®)) for dabigatran reversal in patients undergoing heart transplantation: a cohort of ten patients

BACKGROUND: Novel oral anticoagulants are used in atrial fibrillation. Idarucizumab has been approved for reversal of dabigatran in situations of life-threatening hemorrhage or emergency surgery. OBJECTIVES: We report a single center experience of ten patients on dabigatran therapy who were given id...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Future Sci OA
Egile Nagusiak: Kalmanovich, Eran, Battistella, Pascal, Rouviere, Philippe, Albat, Bernard, Frapier, Jean-Marc, Demaria, Roland, Huet, Fabien, Agullo, Audrey, Mourad, Marc, Colson, Pascal, Leclercq, Florence, Gaudard, Philippe, Roubille, François
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Future Science Ltd 2021
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8015660/
https://ncbi.nlm.nih.gov/pubmed/33815827
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2144/fsoa-2020-0186
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak